Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in California: - Kaiser Permanente-Anaheim — Anaheim, California
- Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- PCR Oncology — Arroyo Grande, California
- Sutter Auburn Faith Hospital — Auburn, California
- Sutter Cancer Centers Radiation Oncology Services-Auburn — Auburn, California
Phase 3 Recruiting Academic/Other
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Sites in California: - Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- Tower Cancer Research Foundation — Beverly Hills, California
- Mercy Cancer Center - Carmichael — Carmichael, California
- Mercy San Juan Medical Center — Carmichael, California
- Enloe Medical Center — Chico, California
Phase 3 Recruiting Industry
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which inc…
Sponsor: Gilead Sciences
NCT ID: NCT05633654
Sites in California: - Alta Bates Summit Medical Center — Berkeley, California
- Community Cancer Institute — Clovis, California
- PIH Health Whittier Hospital — Downey, California
- Compassionate Cancer Care Medical Group - Inc — Fountain Valley, California
- Los Angeles Cancer Network — Los Angeles, California
Phase 3 Recruiting Industry
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early b…
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT06492616
Sites in California: - Comprehensive Blood & Cancer Center — Bakersfield, California
- UCSF Cancer Center Berkeley — Berkeley, California
- Cedars-Sinai Cancer Beverly Hills — Beverly Hills, California
- City of Hope National Medical Center — Duarte, California
- UCSF Wash Cancer CNTR — Fremont, California
Phase 3 Recruiting Industry
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizuma…
Sponsor: AstraZeneca
NCT ID: NCT06103864
Sites in California: - Research Site — Duarte, California
- Research Site — Glendale, California
- Research Site — Sacramento, California
- Research Site — Santa Rosa, California
Phase 3 Recruiting Academic/Other
This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…
Sponsor: NRG Oncology
NCT ID: NCT06500481
Sites in California: - UC San Diego Health System - Encinitas — Encinitas, California
- UC San Diego Moores Cancer Center — La Jolla, California
- UC San Diego Medical Center - Hillcrest — San Diego, California
- California Protons Cancer Therapy Center — San Diego, California
Phase 3 Recruiting Industry
This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participant…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06790693
Sites in California: - Disney Family Cancer Center — Burbank, California
- Scripps Health — La Jolla, California
- Cancer and Blood Specialty Clinic — Los Alamitos, California
- Ellison Institute of Technology — Los Angeles, California
- Palo Alto Medical Foundation Research Center — Palo Alto, California
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-pa…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06926868
Sites in California: - Helios Clinical Research — Cerritos, California
- Local Institution - 0307 — Cerritos, California
- Local Institution - 0308 — Cerritos, California
- Local Institution - 0309 — Cerritos, California
- Local Institution - 0311 — Long Beach, California
Phase 3 Recruiting Industry
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in particip…
Sponsor: AstraZeneca
NCT ID: NCT06952803
Sites in California: - Research Site — La Jolla, California
- Research Site — La Jolla, California
- Research Site — Los Angeles, California
- Research Site — San Diego, California
- Research Site — San Luis Obispo, California
Phase 3 Recruiting Industry
This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcutaneous use) compared with placebo in combination with Phesgo, as maintenance therapy, after…
Sponsor: Hoffmann-La Roche
NCT ID: NCT05894239
Sites in California: - Disney Family Cancer Center — Burbank, California
- City of Hope — Corona, California
- City of Hope Comprehensive Cancer Center — Duarte, California
- City of Hope at Irvine Lennar — Irvine, California
- Ellison Institute of Technology — Los Angeles, California
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in California: - PCR Oncology — Arroyo Grande, California
- Mercy Cancer Center - Carmichael — Carmichael, California
- Mercy San Juan Medical Center — Carmichael, California
- Epic Care-Dublin — Dublin, California
- Mercy Cancer Center - Elk Grove — Elk Grove, California
Phase 1, Phase 2 Recruiting Industry
The purpose of this clinical study is to learn about the safety and effects of the study medicine (called disitamab vedotin) for the possible treatment of people with breast cancer that is hard to treat and has spread in the body (advanced…
Sponsor: Pfizer
NCT ID: NCT06966453
Sites in California: - Los Angeles Cancer Network - Anaheim — Anaheim, California
- City of Hope National Medical Center — Duarte, California
- Los Angeles Cancer Network — Fountain Valley, California
- Los Angeles Hematology Oncology Medical Group — Glendale, California
- City of Hope at Irvine Lennar — Irvine, California
Phase 2 Recruiting Academic/Other
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators o…
Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT01042379
Sites in California: - University of California - Davis, Comprehensive Cancer Center — Davis, California
- City of Hope — Duarte, California
- University of California San Diego — La Jolla, California
- University of Southern California — Los Angeles, California
- HOAG Memorial Hospital Presbyterian — Newport Beach, California
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in California: - Helios Clinical Research — Cerritos, California
- California Research Institute — Los Angeles, California
- Sharp Memorial Hospital — San Diego, California
Phase 2 Recruiting Academic/Other
The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an early stage of breast cancer, can be an effective management of the disease. Partic…
Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT06075953
Sites in California: - Berkeley Outpatient Center — Berkeley, California
- City of Hope -Duarte Cancer Center — Duarte, California
- City of Hope - Lennar Foundation Cancer Center — Irvine, California
- UCLA — Los Angeles, California
- UCSF — San Francisco, California
Phase 2 Recruiting Industry
The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT07102381
Sites in California: - Oncology Institute — Long Beach, California
Phase 2 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…
Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in California: - Los Angeles Cancer Network — Los Angeles, California
- Valkyrie Clinical Trials — Los Angeles, California
- Pih Health Hematology Medical Oncology — Whittier, California
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.
Sponsor: DualityBio Inc.
NCT ID: NCT05785741
Sites in California: - University of California, Davis Comprehensive Cancer Center — Sacramento, California
- UCLA Hematology/Oncology - Santa Monica — Santa Monica, California
Phase 2 Recruiting Industry
This open-label research study is studying (Z)-endoxifen as a possible treatment for pre-menopausal women with ER+/HER2- breast cancer. (Z)-endoxifen belongs to a group of drugs called selective estrogen receptor modulators or "SERM", whic…
Sponsor: Atossa Therapeutics, Inc.
NCT ID: NCT05607004
Sites in California: - California Research Institute — Los Angeles, California
Phase 1, Phase 2 Recruiting Industry
This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents
Sponsor: AstraZeneca
NCT ID: NCT05123482
Sites in California: - Research Site — Duarte, California
- Research Site — Irvine, California
- Research Site — Santa Monica, California
- Research Site — Santa Rosa, California
Phase 2 Recruiting Industry
This is an adaptive Phase 2, open-label, randomized, multi-center study evaluating up to 2 regimens of PCS6422 with capecitabine (Cap) vs. standard dose of Cap alone in patients with advanced or metastatic breast cancer. The goal of the st…
Sponsor: Processa Pharmaceuticals
NCT ID: NCT06568692
Sites in California: - Valkyrie Clinical Trials — Los Angeles, California
- FOMAT Medical Research — Oxnard, California
Phase 1, Phase 2 Recruiting Industry
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with breast cancer. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatmen…
Sponsor: Hoffmann-La Roche
NCT ID: NCT04802759
Sites in California: - City of Hope — Duarte, California
- City of Hope - Orange County Lennar Foundation Cancer Center — Irvine, California
- University of California, San Francisco (UCSF) — San Francisco, California
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center — Santa Monica, California
- Stanford Cancer Institute (SCI) — Stanford, California
Phase 2 Recruiting Academic/Other
This study is being done to determine if stereotactic body radiotherapy (SBRT) when delivered to all sites of disease in participants with 1-5 metastases will increase the length of time before participants' disease gets worse.
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT03808337
Sites in California: - Natera, Inc. (Data and Specimen Analysis Only) — San Carlos, California
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a fi…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT04895709
Sites in California: - Community Cancer Institute — Clovis, California
- USC/Norris Comprehensive Cancer Center — Los Angeles, California
- Hoag Memorial Hospital Presbyterian — Newport Beach, California
Phase 1, Phase 2 Recruiting Industry
This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that has recurr…
Sponsor: AstraZeneca
NCT ID: NCT05417594
Sites in California: - Research Site — La Jolla, California
- Research Site — Los Angeles, California
- Research Site — San Francisco, California